Results for Center for Drug Discovery
A popular antibiotic called rifampicin, used to treat tuberculosis, leprosy, and Legionnaire’s disease, is becoming less effective as the bacteria that cause the diseases develop more resistance.
The breakthrough came when the team, led by Fralin Life Science Institute researcher Zac Mackey, discovered that the parasite Trypanosoma brucei uses a distinct method to perform a biochemical process known as phosphorylation.
The research team targeted the switch that allows the fungus Aspergillus fumigatus to survive in iron-deficient conditions like the human body.
Virginia Tech scientists are working to pinpoint why people with diabetes are prone to developing Alzheimer’s disease.
The symposium's goal is to further collaboration, especially for the discovery, development, and delivery of drugs to treat brain illness.
In this four-year position, which begins July 1, Maria Belen Cassera will conduct peer review of grant applications submitted to the NIH and evaluate them for their scientific merit.
An assistant professor of biochemistry has received a grant to examine the metabolism of the malaria-causing parasite Plasmodium falciparum in order to identify new drug targets.
Research on new polymer additives that enhance the ability of orally administered drugs will result in greater effectiveness and fewer side effects.
Page 2 of 2 | 37 Results